CB1 cannabinoid receptor signalling in Parkinson's disease

Current Opinion in Pharmacology

Volumn 3, Issue 1, 2003, Pages 54-61

  Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ANTIPARKINSON AGENT; BAY 38 7271; BENZYLSULFONYL FLUORIDE; CANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DOPAMINE; DRONABINOL; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; GLUTAMINE; LEVODOPA; METHYLARACHIDONOYLFLUOROPHOSPHORATE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; NOLADIN ETHER; O 1812; OXIDOPAMINE; RECEPTOR SUBTYPE; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG RECEPTOR; ENDOCANNABINOID;

BASAL GANGLION; BRAIN REGION; CELL COMMUNICATION; DYSKINESIA; EXPERIMENTAL MODEL; HUMAN; MOVEMENT (PHYSIOLOGY); NERVE CELL NETWORK; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPTOM; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY;

ANIMALS; BASAL GANGLIA; ENDOCANNABINOIDS; HUMANS; PARKINSON DISEASE; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION;

EID: 0037303024     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00011-5     Document Type: Review

References (55)

1. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
2. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
3. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K: 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
4. Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V: Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Letts 2002, 513:294-298.
5. 1 receptor. J Pharmacol Exp Ther 2002, 301:31020-31024.
6. Di Marzo V, Bisogno T, De Petrocellis L: Anandamide: some like it hot. Trends Pharmacol Sci 2001, 22:346-349.
7. 1 cannabinoid receptors in cultured astrocytes. Eur J neurosci 1999, 11:691-699.
8. Bisogno T, MacCarrone M, De Petrocellis L, Jarrahian A, Finazzi-Agric A, Hillard C, Di Marzo V: The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem 2001, 268: 1982-1989.
9. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D: Brain monoglyceride lipase participating in endocannabinoid inactivation.Proc Natl Acad Sci USA 2002. 99:10819-10824.
10. Romero J, Hillard CJ, Calero M, Rábano A: Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res 2002, 100:85-93.
11. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V: Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 2000, 483:52-56.
12. Mauler F, Mittendorf J, Horváth E, De Vry J: Characterization of the diarylether sulfonylester (-)-(R)-3(2-hydrocymethylindanyl-4-oxy) phenyl-4,4,4-triflouro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 2002, 302:359-368.
13. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL, Davis JB, Dasse O, Mahadevan A, Razdan RK, Martin BR: Highly selective CB(1)/VR(1) vanilloid receptor 'hybrid' ligands. Biochem Biophys Res Commun 2001, 281:444-451.
14. Wilson RI, Nicoll RA: Endocannabinoid signaling in the brain. Science 2002, 296:678-682. Comprehensive study demonstrating the widely held view that a key action of endocannabinoids is to rescue neurotransmitter release.
15. Schlicker E, Kathmann M: Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001, 22:565-572.
16. Bibbiani F, Oh JD, Chase TN: Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
17. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U: Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001, 16:515-520.
18. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000, 54:1589-1595.
19. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN: Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1999, 290:1034-1040.
20. Henry B, Fox SH, Crossman AR, Brotchie JM: Mu-and delta-opiod receptor antagonists reduced levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 2001, 171:139-146.
21. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM: Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distint: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001, 16:642-650.
22. Nash JE, Brotchie JM: Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Mov Disord 2002, 17:455-466.
23. Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maeuf Y, Hille C, Brotchie JM, Crossman AR: Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2000, 165:136-142.
24. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P: Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 depamine agonist increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000, 162:321-327.
25. Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM: Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Exp Neurol 2001, 172:189-198.
26. Bezard E, Ravenscroft P, Grossman AR, Brotchie JM: Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4phenyl-1,2,3,4,6-tetrahydropyridine monkeys. Neurobiol Dis 2001, 8:2343-2350.
27. 1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 2000, 21:1735-1742.
28. Hohmann AG, Herkenham M: Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapase 2000, 37:71-80.
29. 1-like and glutamic acid decarboxylasse-like immunoreactivities in the brain of Xenopus laevis. Cell Tissues Res 2001, 306:391-398.
30. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agric A, Maccarrone M: Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 2002, 22:6900-6907.
31. 1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001, 85:468-471.
32. Gerdeman GL, Ronesi J, Lovinger DM: Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci 2002, 5:446-451.
33. Hermann H, Marsicano G, Lutz B: Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002, 109:451-460.
34. Maneuf YP, Brotchie JM: Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 1997, 120:1397-1398.
35. 1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 2001, 40:918-926.
36. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D: Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999, 2:358-363.
37. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM: Cannainoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001, 57:2108-2111.
38. Sañudo-Peña MC, Tsou K, Walter JM: Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999, 65:703-713.
39. Wallmichrath I, Szabo B: Analysis of the effect of cannabinoids on GABAergic neurotransmission in the substantia nigra pars reticulata. Naunyn Schmiedebergs Arch Pharmacol 2002, 365:326-334.
40. Wallmichrath I, Szabo B: Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse. Neuroscience 2002, 113:671-682.
41. Sañudo-Peña MC, Patrick SL, Khen S, Patrick RL, Tsou K, Walker JM: Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci Lett 1998; 248:171-174.
42. Melis M, Gessa GL, Diana M: Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 2000, 24:993-1006.
43. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG: Cannabis induced dopamine release: an in vivo SPECT study. Psychiatry Res 2001, 107:173-177.
44. 1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 2001, 14:1827-1832.
45. 1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 2001, 169:400-406.
46. 1 receptor mRNA levels in the caudate-putamen. Life Sci 2000, 66:485-494.
47. 1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett 1999, 279:71-74.
48. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE: Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001, 21:6853-6861.
49. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM: Enhanced levels of endrogenous cannabioids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000, 14:1432-1438.
50. Brotchie JM: Adjuncts to dopamine replacement: a progmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998, 13:871-876.
51. Maneuf YP, Crossman AR, Brothie JM: The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 1997, 148:265-270.
52. Pertwee RG, Wickens AP: Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 1991, 30:237-244.
53. Meschler JP, Howlett AC, Madra BK: Cannabinoid receptor agonist and antagonist effects on motor functons in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl) 2001, 156:79-85.
54. Fox SH, Henry B, Hill M, Crossman AR, Brotchie JM: Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned non-human primate model of Parkinson's disease. Mov Disord, in press.
55. 1 cannabinoid receptor-modulating compounds on the hyperkinesia induced by high dose L-DOPA in the reserpine-treated rat model of Parkinson's disease. Mov Disord, in press.